The metabolism of neuronal iron and its pathogenic role in neurological disease: review. Ann N Y Acad Sci 2004; 1012: 14–26., .
Youdim MB. Role of iron in neurodegenerative disorders. Top Magn Reson Imaging 2006; 17: 5–17.,
The relation between brain iron and NMR relaxation times: an in vitro study. Magn Reson Med 1996; 35: 56–61., , , et al.
Imaging iron stores in the brain using magnetic resonance imaging. Magn Reson Imaging 2005; 23: 1–25., , , et al.
Establishing a baseline phase behavior in magnetic resonance imaging to determine normal vs. abnormal iron content in the brain. J Magn Reson Imaging 2007; 26: 256–264., , , et al.
High-field MRI of brain cortical substructure based on signal phase. Proc Natl Acad Sci USA 2007; 104: 11796–11801., , , et al.
The correlation between phase shifts in gradient-echo MR images and regional brain iron concentration. Magn Reson Imaging 1999; 17: 1141–1148., , , , .
Chakeres DW. Enhanced gray and white matter contrast of phase susceptibility-weighted images in ultra-high-field magnetic resonance imaging. J Magn Reson Imaging 2003; 18: 284–290., , ,
Susceptibility weighted imaging (SWI). Magn Reson Med 2004; 52: 612–618., , ,
Clinical applications of neuroimaging with susceptibility-weighted imaging. J Magn Reson Imaging 2005; 22: 439–450., , , et al.
Magnetic resonance imaging and spectroscopy of hepatic iron overload. Radiology 1985; 154: 137–142., , , et al.
Nuclear magnetic resonance of iron and copper disease states. Am J Roentgenol 1983; 141: 943–948., , , et al.
MRI of brain iron. Am J Roentgenol 1986; 147: 103–110., , , et al.
Haughton VM. T1 and T2 measurements on a 1.5-T commercial MR imager. Radiology 1989; 171: 273–276., , , ,
Helpern JA. Assessment of relative brain iron concentrations using T2-weighted and T2*-weighted MRI at 3 Tesla. Magn Reson Med 1994; 32: 335–341., , , ,
MR imaging of human brain at 3.0 T: preliminary report on transverse relaxation rates and relation to estimated iron content. Radiology 1999; 210: 759–767., , , et al.
MR evaluation of age-related increase of brain iron in young adult and older normal males. Magn Reson Imaging 1997; 15: 29–35., , , et al.
Marder SR. Field dependent transverse relaxation rate increase may be a specific measure of tissue iron stores. Magn Reson Med 1993; 29: 459–464., , , ,
Assessment of brain iron and neuronal integrity in patients with Parkinson’s disease using novel MRI contrasts. Mov Disord 2007; 22: 334–340., , , et al.
Magnetic field correlation imaging. Magn Reson Med 2006; 55: 1350–1361., , , et al.
Diffusion tensor imaging of deep gray matter brain structures: effects of age and iron concentration. Neurobiol Aging 2008; Epub ahead of print, PMID 18513834., , , .
The effect of age on the non-haemin iron in the human brain. J Neurochem 1958; 3: 41–51., .
Normal deposition of brain iron in childhood and adolescence: MR imaging at 1.5 T. Radiology 1989; 172: 381–385., , , et al.
Age, gender, and hemispheric differences in iron deposition in the human brain: an in vivo MRI study. Neuroimage 2008; 40: 35–42., , .
Iron metabolism in parkinsonian syndromes. Mov Disord 2006; 21: 1299–1310.,
Increased nigral iron content in postmortem parkinsonian brain. Lancet 1987; 2: 1219–1220., , , et al.
Increased iron (III) and total iron content in post mortem substantia nigra of parkinsonian brain. J Neural Transm 1988; 74: 199–205., , , et al.
Parkinson-plus syndrome: diagnosis using high field MR imaging of brain iron. Radiology 1986; 159: 493–498., , , et al.
T1 and T2 in the brain of healthy subjects, patients with Parkinson disease, and patients with multiple system atrophy: relation to iron content. Radiology 1999; 211: 489–495., , , et al.
Brain ferritin iron as a risk factor for age at onset in neurodegenerative diseases. Ann N Y Acad Sci 2004; 1012: 224–236., , , , .
Gee M. Midbrain iron content in early Parkinson disease: a potential biomarker of disease status. Neurology 2008; 70: 1411–1417., ,
Genetic, clinical, and radiographic delineation of Hallervorden–Spatz syndrome. N Engl J Med 2003; 348: 33–40., , , et al.
Brain MRI in neurodegeneration with brain iron accumulation with and without PANK2 mutations. AJNR Am J Neuroradiol 2006; 27: 1230–1233., , , ,
Relaxation and susceptibility MRI characteristics in Hallervorden–Spatz syndrome. J Magn Reson Imaging 2007; 25: 715–720., , , ,
Iron: a new target for pharmacological intervention in neurodegenerative diseases. Semin Pediatr Neurol 2006; 13: 186–197., .
Myelin breakdown and iron changes in Huntington’s disease: pathogenesis and treatment implications. Neurochem Res 2007; 32: 1655–1664., , , et al.
Mechanisms of neurodegeneration in Huntington’s disease. Eur J Neurosci 2008; 27: 2803–2820., .
Increased basal ganglia iron levels in Huntington disease. Arch Neurol 1999; 56: 569–574., , , ,
MR relaxometry in Huntington’s disease: correlation between imaging, genetic and clinical parameters. J Neurol Sci 2007; 263: 20–25., , , et al.
Aluminum, iron, and zinc ions promote aggregation of physiological concentrations of beta-amyloid peptide. J Neurochem 1993; 61: 1171–1174., , , et al.
Iron accumulation in Alzheimer disease is a source of redox-generated free radicals. Proc Natl Acad Sci USA 1997; 94: 9866–9868., , , .
In vivo evaluation of brain iron in Alzheimer disease using magnetic resonance imaging. Arch Gen Psychiatry 2000; 57: 47–53., , , et al.
Quantitative MR imaging R2 relaxometry in elderly participants reporting memory loss. AJNR Am J Neuroradiol 2006; 27: 430–439., , , ,
Correlation of proton transverse relaxation rates (R2) with iron concentrations in postmortem brain tissue from Alzheimer’s disease patients. Magn Reson Med 2007; 57: 172–180., St. , , et al.
In vivo visualization of Alzheimer’s amyloid plaques by magnetic resonance imaging in transgenic mice without a contrast agent. Magn Reson Med 2004; 52: 1263–12671., Jr., , , et al.
Noninvasive in vivo MRI detection of neuritic plaques associated with iron in APP[V717I] transgenic mice, a model for Alzheimer’s disease. Magn Reson Med 2005; 53: 607–613., , , , .
Detection of Alzheimer’s amyloid in transgenic mice using magnetic resonance microimaging. Magn Reson Med 2003; 50: 293–302., , , et al.
Transverse relaxation time reflects brain amyloidosis in young APP/PS1 transgenic mice. Magn Reson Med 2007; 58: 179–184., ,
Prevalence and risk factors of cerebral microbleeds: the Rotterdam Scan Study. Neurology 2008; 70: 1208–1214., , , et al.
Brain microbleeds and cognitive function. Stroke 2007; 38: 1730–1731.
Brain microbleeds, amyloid plaques, intellectual deterioration, and arterial stiffness. Hypertension 2008; 51: e20; author reply e21..
Prevalence and severity of microbleeds in a memory clinic setting. Neurology 2006; 66: 1356–1360., , , , , .
Reduced signal intensity on MR images of thalamus and putamen in multiple sclerosis: increased iron content?Am J Roentgenol 1987; 149: 357–363., , , , .
MRI T2 shortening (“black T2”) in multiple sclerosis: frequency, location, and clinical correlation. Neuroreport 2000; 11: 15–21., ,
Deep grey matter “black T2” on 3 tesla magnetic resonance imaging correlates with disability in multiple sclerosis. Mult Scler 2007; 13: 880–883., , , et al.
Prediction of longitudinal brain atrophy in multiple sclerosis by gray matter magnetic resonance imaging T2 hypointensity. Arch Neurol 2005; 62: 1371–1376., , , et al.
Gray matter T2 hypointensity is related to plaques and atrophy in the brains of multiple sclerosis patients. J Neurol Sci 2001; 185: 19–26., , , .
Quantitative assessment of iron accumulation in the deep gray matter of multiple sclerosis by magnetic field correlation imaging. AJNR Am J Neuroradiol 2007; 28: 1639–1644., , , et al.
Cognitive impairment is associated with subcortical magnetic resonance imaging grey matter T2 hypointensity in multiple sclerosis. Mult Scler 2006; 12: 437–444., , , , .